Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers

in portfolio news

Curetis N.V. (Euronext: CURE, the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced the installation of its milestone 150th Unyvero Analyzer worldwide.

Curetis has now grown its installed base of Unyvero Analyzers to 151 as of 31 January 2017. This compares with 103 Analyzers as of the end of 2015, 113 at mid-2016 and 121 as of 30 September 2016.

“We are very pleased to reach this important installed base target, which represents 46% growth in system installations over the course of 2016 and the first month of 2017,” said Dr. Oliver Schacht, CEO of Curetis. “As expected, we have started to see significant momentum in placement rates beginning in Q4, 2016, and continuing into early 2017 following the completion of the build out of our EMEA direct sales team in Q3, 2016. Since then, our sales pipeline has expanded dramatically, both in terms of number and quality of prospective customers. We expect this pipeline growth to continue as we approach key inflection points in strategic markets such as the U.S., where our application for 510(k) clearance is currently under review by the FDA. Overall we are now well positioned to deliver further growth in 2017.”